EA201490641A1 - Способы снижения уровней липопротеина(а) посредством введения ингибитора пропротеинконвертазы субтилизин/кексин-9 (pcsk9) - Google Patents

Способы снижения уровней липопротеина(а) посредством введения ингибитора пропротеинконвертазы субтилизин/кексин-9 (pcsk9)

Info

Publication number
EA201490641A1
EA201490641A1 EA201490641A EA201490641A EA201490641A1 EA 201490641 A1 EA201490641 A1 EA 201490641A1 EA 201490641 A EA201490641 A EA 201490641A EA 201490641 A EA201490641 A EA 201490641A EA 201490641 A1 EA201490641 A1 EA 201490641A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pcsk9
levels
methods
inhibitor
protroykinvertasy
Prior art date
Application number
EA201490641A
Other languages
English (en)
Other versions
EA028278B1 (ru
Inventor
Гари Сверголд
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46881178&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490641(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201490641A1 publication Critical patent/EA201490641A1/ru
Publication of EA028278B1 publication Critical patent/EA028278B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении приводятся способы снижения уровней липопротеина(a) (Lp(a)) у пациентов. Способы настоящего изобретения включают выбор пациента, у которого наблюдаются повышенные уровни сывороточного Lp(a), и введение пациенту фармацевтического препарата, содержащего ингибитор PCSK9. В некоторых осуществлениях ингибитором PCSK9 является антитело анти-РСSK9, такое как пример антитела, описанного в настоящем документе как mAb316Р.
EA201490641A 2011-09-16 2012-09-12 СПОСОБЫ СНИЖЕНИЯ УРОВНЕЙ ЛИПОПРОТЕИНА(а) ПОСРЕДСТВОМ ВВЕДЕНИЯ ИНГИБИТОРА ПРОПРОТЕИНКОНВЕРТАЗЫ СУБТИЛИЗИН/КЕКСИН-9 (PCSK9) EA028278B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161535392P 2011-09-16 2011-09-16
US201161559162P 2011-11-14 2011-11-14
US201261641321P 2012-05-02 2012-05-02
PCT/US2012/054756 WO2013039969A1 (en) 2011-09-16 2012-09-12 METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)

Publications (2)

Publication Number Publication Date
EA201490641A1 true EA201490641A1 (ru) 2014-06-30
EA028278B1 EA028278B1 (ru) 2017-10-31

Family

ID=46881178

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490641A EA028278B1 (ru) 2011-09-16 2012-09-12 СПОСОБЫ СНИЖЕНИЯ УРОВНЕЙ ЛИПОПРОТЕИНА(а) ПОСРЕДСТВОМ ВВЕДЕНИЯ ИНГИБИТОРА ПРОПРОТЕИНКОНВЕРТАЗЫ СУБТИЛИЗИН/КЕКСИН-9 (PCSK9)

Country Status (21)

Country Link
US (2) US10076571B2 (ru)
EP (3) EP2756004B1 (ru)
JP (2) JP6158813B2 (ru)
KR (1) KR101964031B1 (ru)
CN (2) CN111789944A (ru)
AR (1) AR087881A1 (ru)
AU (1) AU2012308797B2 (ru)
BR (1) BR112014005522A2 (ru)
CA (1) CA2848201C (ru)
CL (1) CL2014000605A1 (ru)
CO (1) CO6910163A2 (ru)
EA (1) EA028278B1 (ru)
ES (2) ES2953713T3 (ru)
IL (1) IL231011B (ru)
MA (1) MA35430B1 (ru)
MX (1) MX363642B (ru)
MY (1) MY170089A (ru)
SG (1) SG2014010524A (ru)
TW (1) TWI601740B (ru)
WO (1) WO2013039969A1 (ru)
ZA (1) ZA201401114B (ru)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
AR084938A1 (es) 2011-01-28 2013-07-10 Sanofi Sa Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AU2012308797B2 (en) 2011-09-16 2017-06-01 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
US10111953B2 (en) * 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI682780B (zh) * 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
KR20160024906A (ko) 2013-06-07 2016-03-07 사노피 바이오테크놀로지 Ｐｃｓｋ9의 억제제를 투여함에 의한 죽상경화증의 억제 방법
JP6846931B2 (ja) * 2013-10-11 2021-03-24 サノフィ・バイオテクノロジー 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用
EP3882273A1 (en) 2013-11-12 2021-09-22 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
CN106029096A (zh) * 2014-02-14 2016-10-12 瑞泽恩制药公司 用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
BR112016024379A2 (pt) 2014-04-25 2017-10-10 Univ Pennsylvania variantes ldlr e seu uso em composições para reduzir os níveis de colesterol
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
MX2017000628A (es) * 2014-07-16 2017-04-27 Sanofi Biotechnology Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
KR20170029613A (ko) * 2014-07-16 2017-03-15 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
JP6940411B2 (ja) * 2015-03-13 2021-09-29 エスペリオン・セラピューティクス・インコーポレイテッドＥｓｐｅｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法
EP3337828A1 (en) 2015-08-18 2018-06-27 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
CN109121421B (zh) 2015-12-11 2022-11-01 宾夕法尼亚州大学信托人 用于治疗家族性高胆固醇血症的基因疗法
KR20180093068A (ko) 2015-12-31 2018-08-20 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Pcsk9 항체, 이의 항원-결합 단편 및 이의 의학적 적용
WO2017118307A1 (zh) 2016-01-05 2017-07-13 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN107474140B (zh) * 2016-06-08 2022-06-03 常州博嘉生物医药科技有限公司 Pcsk9特异性的结合蛋白mv072及其应用
US11883470B2 (en) 2016-07-25 2024-01-30 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
JP7103748B2 (ja) * 2016-10-05 2022-07-20 サッポロビール株式会社 Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP2020510648A (ja) * 2017-02-20 2020-04-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 家族性高コレステロール血症を処置するための遺伝子治療
MX2019012083A (es) 2017-04-13 2019-11-21 Cadila Healthcare Ltd Nueva vacuna de peptidos contra la pcsk9.
WO2019173530A1 (en) * 2018-03-06 2019-09-12 Sanofi Biotechnology Use of pcsk9 inhibitor for reducing cardiovascular risk
WO2020010024A1 (en) * 2018-07-02 2020-01-09 Abcentra, Llc Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis
CN113574055B (zh) 2019-01-18 2024-07-23 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
AU670793B2 (en) 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
AU2548097A (en) 1996-03-26 1997-10-17 Eli Lilly And Company Formulations of ob protein
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2317411C (en) 1998-01-30 2005-06-28 Scios Inc. Controlled release delivery of peptide or protein
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
EP1067182A3 (en) 1999-07-08 2001-11-21 Helix Research Institute Secretory protein or membrane protein
US7129338B1 (en) 1999-07-08 2006-10-31 Research Association For Biotechnology Secretory protein or membrane protein
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
CA2399727A1 (en) 2000-02-07 2001-08-09 Millennium Pharmaceuticals, Inc. Narc-1, subtilase-like homologs
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
EP3190126A1 (en) 2000-05-26 2017-07-12 Immunex Corporation Use of interleukin-4 receptor (il-4r) antibodies and compositions thereof
MXPA03002046A (es) 2000-09-08 2003-07-24 Massachusetts Inst Technology Composiciones analogos de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
IE20040308A1 (en) 2003-05-02 2004-11-17 Univ College Cork Nat Univ Ie Light emitting diodes and the manufacture thereof
US7638606B2 (en) 2003-11-07 2009-12-29 Immunex Corporation Antibodies that bind interleukin-4 receptor
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US20060147945A1 (en) 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
ES2386578T3 (es) 2006-05-05 2012-08-23 Isis Pharmaceuticals, Inc. Compuestos y procedimientos para modular la expresión de PCSK9
ES2366973T3 (es) * 2006-05-05 2011-10-27 Isis Pharmaceuticals, Inc. Compuestos y procedimiento para modular la expresión génica.
KR101406811B1 (ko) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
RS61650B1 (sr) 2006-10-02 2021-04-29 Regeneron Pharma Visokoafinitetna humana antitela za humani il-4 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JP5588175B2 (ja) 2006-11-07 2014-09-10 メルク・シャープ・アンド・ドーム・コーポレーション Ｐｃｓｋ９のアンタゴニスト
EP2083859A4 (en) 2006-11-07 2010-11-24 Merck Sharp & Dohme ANTAGONISTS OF PCSK9
EP2083860A4 (en) 2006-11-07 2010-05-26 Merck Sharp & Dohme PCSK9 ANTAGONISTS
WO2008133647A2 (en) 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonists of pcsk9
EP2453016A1 (en) 2006-11-27 2012-05-16 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
WO2008073300A2 (en) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
CN101679527A (zh) 2007-04-13 2010-03-24 诺瓦提斯公司 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法
CN101687927B (zh) 2007-05-15 2013-10-30 霍夫曼-拉罗奇有限公司 针对g蛋白偶联的受体（gpcr）的抗体
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2009042765A1 (en) 2007-09-25 2009-04-02 The Regents Of The University Of California Methods of modulating prokineticin 2 for treatment of stress response and anxiety-related disorders
JP2011501952A (ja) 2007-10-26 2011-01-20 シェーリング コーポレイション 脂質障害およびコレステロール障害を治療するための抗ｐｃｓｋ９および方法
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
ES2563483T3 (es) 2008-04-11 2016-03-15 Chugai Seiyaku Kabushiki Kaisha Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
SI2331090T1 (en) 2008-09-19 2018-04-30 Pfizer Inc. Stable liquid antibody formulation
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
EP2442798A4 (en) 2009-06-18 2013-03-13 Wyeth Llc LYOPHILIZED FORMULATIONS FOR SMALL-SCALE MODULAR IMMUNOPHARMACEUTICAL AGENTS
WO2011028938A1 (en) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
WO2011037791A1 (en) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonists of pcsk9
WO2011039578A1 (en) 2009-10-02 2011-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
CN102639150A (zh) 2009-10-30 2012-08-15 默沙东公司 Ax213和ax132 pcsk9拮抗剂和变体
AU2010313381A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX1 and AX189 PCSK9 antagonists and variants
PT3721904T (pt) 2009-11-20 2021-11-15 Biocon Ltd Formulações de anticorpo t1h
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
SG183867A1 (en) 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
GB201005005D0 (en) 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
EP3733711A1 (en) 2010-10-06 2020-11-04 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
CA2817015A1 (en) 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
SG191219A1 (en) 2010-12-22 2013-07-31 Genentech Inc Anti-pcsk9 antibodies and methods of use
AR084938A1 (es) 2011-01-28 2013-07-10 Sanofi Sa Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
MX2013009258A (es) 2011-02-11 2013-10-17 Novartis Ag Antagonistas de pcsk9.
AR088782A1 (es) 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20140004122A1 (en) 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
US20140161821A1 (en) 2011-07-14 2014-06-12 Pfizer Inc. Treatment with anti-pcsk9 antibodies
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
AU2012308797B2 (en) 2011-09-16 2017-06-01 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9)
WO2013158984A1 (en) 2012-04-19 2013-10-24 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
CA2874244A1 (en) 2012-05-25 2013-11-28 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
EP2703009A1 (en) 2012-08-31 2014-03-05 Sanofi Combination treatments involving antibodies to human PCSK9
EP2703008A1 (en) 2012-08-31 2014-03-05 Sanofi Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
EP2706070A1 (en) 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
KR20160024906A (ko) 2013-06-07 2016-03-07 사노피 바이오테크놀로지 Ｐｃｓｋ9의 억제제를 투여함에 의한 죽상경화증의 억제 방법
JP6846931B2 (ja) 2013-10-11 2021-03-24 サノフィ・バイオテクノロジー 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用
EP3882273A1 (en) 2013-11-12 2021-09-22 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
CN106029096A (zh) 2014-02-14 2016-10-12 瑞泽恩制药公司 用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法
US20150283236A1 (en) 2014-03-17 2015-10-08 Marie Baccara-Dinet Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
MX2017000628A (es) 2014-07-16 2017-04-27 Sanofi Biotechnology Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
KR20170029613A (ko) 2014-07-16 2017-03-15 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
EA039310B1 (ru) 2015-02-26 2022-01-12 Санофи Байотекнолоджи Способы снижения сердечно-сосудистого риска
EP3337828A1 (en) 2015-08-18 2018-06-27 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
US10933134B2 (en) 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer

Also Published As

Publication number Publication date
JP6158813B2 (ja) 2017-07-05
MA35430B1 (fr) 2014-09-01
US20180333490A1 (en) 2018-11-22
EP2756004A1 (en) 2014-07-23
NZ621135A (en) 2016-10-28
CO6910163A2 (es) 2014-03-31
US20130243784A1 (en) 2013-09-19
ZA201401114B (en) 2015-04-29
EP3536712B1 (en) 2023-05-31
EP4252857A2 (en) 2023-10-04
MY170089A (en) 2019-07-04
JP2017206520A (ja) 2017-11-24
IL231011B (en) 2020-01-30
CN111789944A (zh) 2020-10-20
EP4252857A3 (en) 2023-12-06
EA028278B1 (ru) 2017-10-31
ES2773111T3 (es) 2020-07-09
TWI601740B (zh) 2017-10-11
MX2014002158A (es) 2014-05-07
KR20140075728A (ko) 2014-06-19
EP2756004B1 (en) 2019-12-25
AU2012308797A1 (en) 2014-03-13
TW201329099A (zh) 2013-07-16
KR101964031B1 (ko) 2019-04-02
SG2014010524A (en) 2014-06-27
EP3536712A1 (en) 2019-09-11
AR087881A1 (es) 2014-04-23
IL231011A0 (en) 2014-03-31
CN103930444B (zh) 2020-08-04
BR112014005522A2 (pt) 2017-03-21
CN103930444A (zh) 2014-07-16
WO2013039969A1 (en) 2013-03-21
AU2012308797B2 (en) 2017-06-01
US10076571B2 (en) 2018-09-18
CL2014000605A1 (es) 2014-08-22
ES2953713T3 (es) 2023-11-15
CA2848201A1 (en) 2013-03-21
CA2848201C (en) 2020-10-27
US11116839B2 (en) 2021-09-14
JP2014527967A (ja) 2014-10-23
MX363642B (es) 2019-03-28

Similar Documents

Publication Publication Date Title
EA201490641A1 (ru) Способы снижения уровней липопротеина(а) посредством введения ингибитора пропротеинконвертазы субтилизин/кексин-9 (pcsk9)
EA201592302A1 (ru) Способы снижения уровня остаточного холестерина и других фракций липопротеинов путем введения ингибитора пропротеиновой конвертазы субтилизин-кексинового типа 9 (pcsk9)
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
EA201291436A1 (ru) Производные гексафторизопропил карбамата, их получение и их терапевтическое применение
EA201101111A1 (ru) Алкиламинозамещенные дицианопиридины и их пролекарства в виде сложных эфиров с аминокислотами
EA201391561A1 (ru) Новые соединения-модуляторы gpr-119
EA201301209A1 (ru) Производные пирролотриазинона в качестве ингибиторов p13k
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201300558A1 (ru) Соединения и способы для купирования боли
MX2014000578A (es) Tratamiento con anticuerpos anti-pcsk9.
EA201291282A1 (ru) Азотсодержащие гетероарильные соединения
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201500432A1 (ru) Соединения боронатного эфира и его фармацевтические составы
EA201391157A1 (ru) Антагонисты pcsk9
EA201490599A1 (ru) Соединения триазолопиридина в качестве ингибиторов фосфодиэстеразы pde10a
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
EA201890519A1 (ru) Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
EA201301019A1 (ru) Бензодиоксановые ингибиторы продуцирования лейкотриена
EA201991704A3 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201690889A1 (ru) Режимы дозирования для применения ингибиторов pcsk9
EA201201296A1 (ru) Способы лечения диабетических язв стопы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM